- March 15, 2022
- Newsletter
- 617-430-5616
Menu
ADVERTISEMENT
ADVERTISEMENT
Brand Name :
Haldol Decanoate, Haldol, Peridol, Haloperidol LA
Synonyms :
haloperidol
Class :
Antipsychotics, 1st generation
Actions and Spectrum:
haloperidol is a potent antipsychotic medication that acts primarily by blocking dopamine receptors in the brain. Its actions and therapeutic spectrum include:
No drug interaction found for haloperidol and .
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
when both drugs are combined, there may be an increase in qtc interval
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
hydroxyzine may enhance the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of opioid agonists
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
anticholinergic agents increase the anticholinergic effect of glycopyrrolate
anticholinergic agents decrease the efficacy of levosulpride
It may enhance QTc interval when combined with perphenazine
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
QTc interval is increased both by lenvatinib and haloperidol
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A strong enhancers of the small intestine may reduce the bioavailability of haloperidol
when used together, entrectinib and haloperidol both increase the QTc interval
when used together, encorafenib and haloperidol both increase the QTc interval
may enhance the QTc-prolonging effects of haloperidol
azelastine may enhance the CNS depressant effect of CNS Depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of flunarizine
may increase the QTc interval when combined
may increase the CNS depressant effect
glycopyrrolate inhaled and formoterol
may increase the QTc interval when combined
may decrease the therapeutic effect of cabergoline
antiarrhythmics (QT prolonging class IC)
they increase the QT prolongation of haloperidol
haloperidol decreases the effect of urea cycle disorder agents
haloperidol increases the effect of CYP3A4 inhibitors
acetylcholinesterase inhibitors
they decrease the effect of anticholinergic agents
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the QTc-prolonging effect of haloperidol
may enhance the QTc-prolonging effect of haloperidol
may enhance the QTc-prolonging effect of haloperidol
may enhance the QTc-prolonging effect of haloperidol
may enhance the QTc-prolonging effect of haloperidol
QT-prolongers increase the effect of QTc prolongation of haloperidol
QT-prolongers increase the effect of QTc prolongation of haloperidol
QT-prolongers increase the effect of QTc prolongation of haloperidol
QT-prolongers increase the effect of QTc prolongation of haloperidol
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with haloperidol
QT-prolongers increase the effect of QTc-prolongation of haloperidol
QT-prolongers increase the effect of QTc-prolongation of haloperidol
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
the effect of haloperidol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of haloperidol by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it increases the QT-c prolonging effect of gilteritinib
qt-prolonging agents: it may increase the qtc-prolonging effect of haloperidol
QT-prolongers increase the QTc extending effect of haloperidol
QT-prolonging agents increase the effect of QTc prolongation of haloperidol
it may increase the neurotoxic effect of antipsychotic agents
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effect of amphetamines
it may increase the risk of adverse effect of amphetamines
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the toxic effect of amphetamines
may increase the hypotensive effect of blood pressure-lowering agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the toxic effect of seizure threshold-lowering potential agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
antiarrhythmics (QT prolonging class III)
they increase the QT prolongation of haloperidol
it increases the QTc-prolonging effect of domperidone
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.5 - 5
mg
every 8 hrs
do not exceed the dose of more than 30 mg/day
0.5 - 2
mg
every 8 hrs
moderate: 0.5 to 2 mg orally every 8-12 hours
severe: 3-5 mg orally every 8-12 hours; do not exceed the dose of more than 30 mg/day
2-5 mg intramuscularly (prompt acting) every 4-8 hours as required. In case of acute agitation dose may be required every hour. Do not exceed the dose more than 20 mg/day
(Off-Label)
2-10 mg initially, repeat the bolus dose every 15-30 minutes, sequence wise coupling the initial bolus
After achieving stagnation, administer 25% of last bolus every 6 hours
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.25 - 1
mg
every 12 hrs
5 - 7
days
0.5
mg/day
every 12 hrs
5 - 7
days
Indicated for Psychosis/Sedation, Schizophrenia
For <3 years:
Safety and efficacy are not seen
For 3-12 years (15-40 kg):
0.25-0.5 mg/day orally every 8-12 hours initially; increase by 0.5 mg/day, every 5-7 days as required;
Maintenance dose:
0.05-0.15 mg/kg per day orally every 8-12 hours
For 6-12 years (prompt-acting):
1-3 mg intramuscularly every 4-8 hours as required; do not exceed 0.15 mg/kg per day
For >12 years:
Moderate disease, 0.5-2 mg orally every 8-12 hours initially; in severe disease, 3-5 mg orally every 8-12 hours; do not exceed more than 30 mg/day
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.25 - 0.5
mg
Tablet
Orally
every 8 hrs
Initially 0.25-0.5 mg orally every 8-12 hours
(Off-Label)
0.25-0.5 mg intravenously every 4 hours
Frequency not defined
Akathisia
Dystonia
Parkinsonism
Sedation
Weight gain
Anxiety
Anorexia
Dyspepsia
Lens opacities
Priapism
Black Box Warning:
Antipsychotic drugs have been associated with an increased risk of death in elderly patients with dementia-related psychosis. In 2005, the US Food and Drug Administration (FDA) issued a black box warning regarding the use of atypical antipsychotics in elderly patients with dementia-related psychosis due to an increased risk of mortality.
The warning indicated that these drugs are not approved for the treatment of dementia-related psychosis. Subsequently, clinical studies have shown that the risk of death is highest during the first few months of treatment with antipsychotic drugs, and that the risk may be higher with the use of some atypical antipsychotic drugs compared to others.
As a result, the use of antipsychotic drugs in elderly patients with dementia-related psychosis is generally discouraged unless the patient is experiencing severe symptoms that significantly impair their quality of life, and other treatment options have been exhausted.
Contraindication/Caution:
There are several contraindications and precautions associated with the use of haloperidol, including:
Pregnancy consideration:
No well-controlled studies are reported in pregnant women, but cases of limb malformations are observed
Breastfeeding warnings:
haloperidol is known for its excretion in breastmilk. Lactating females should not nurse the infant during treatment
Pregnancy category:
Pharmacology:
haloperidol is a medication that belongs to the class of drugs called antipsychotics. It is used to treat various psychiatric disorders, including schizophrenia, mania, and Tourette’s syndrome.
Pharmacologically, haloperidol works by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter that plays a key role in regulating mood, behavior, and movement. By blocking dopamine receptors, haloperidol reduces the activity of dopamine in the brain, which can help to alleviate the symptoms of psychosis.
haloperidol is primarily metabolized by the liver and excreted in the urine. The drug has a half-life of approximately 20 hours, meaning that it takes about 20 hours for half of the drug to be eliminated from the body.
Common side effects of haloperidol include drowsiness, dizziness, dry mouth, constipation, and blurred vision. More serious side effects may include tardive dyskinesia (a movement disorder), neuroleptic malignant syndrome (a potentially life-threatening condition), and an increased risk of stroke in elderly patients with dementia.
Pharmacodynamics:
The pharmacodynamics of haloperidol involves its mechanism of action, effects on neurotransmitters, and its therapeutic and side effects.
haloperidol acts primarily as a dopamine receptor antagonist, specifically at D2 dopamine receptors in the brain. It blocks the binding of dopamine to its receptors, reducing the activity of dopamine in certain areas of the brain. This is believed to be the basis for its antipsychotic effects.
In addition to its effects on dopamine, haloperidol also has activity at other receptors in the brain, including serotonin, histamine, and adrenergic receptors. This can lead to side effects such as sedation, orthostatic hypotension, and weight gain.
Pharmacokinetics:
Absorption
The bioavailability is 60-70%
Onset of action takes place in 30-60 minutes
Duration of action is 2-4 weeks
Peak plasma concentration is achieved in 2-6 hours (oral); 10-20 minutes(intramuscular); and 6-7 days (decanoate)
Distribution
Protein bound is 90%
The volume of distribution is 8-18 L/kg
Metabolism
The drug is metabolized by hepatic P450 enzyme CYP3A4
The metabolites formed are Hydroxy haloperidol
The enzymes inhibited are CYP2D6
Elimination and Excretion
The half-life is achieved in 18 hours
The drug is excreted 30% in urine and 15% in feces
Administration
haloperidol is typically administered orally, either as a tablet or a liquid. The medication can be taken with or without food, although taking it with food may help to reduce gastrointestinal side effects.
The dose of haloperidol will vary depending on the condition being treated and the individual patient’s response to the medication. The medication is usually started at a low dose and gradually increased as needed, based on the patient’s symptoms and tolerability.
In addition to oral administration, haloperidol is also available in injectable form for use in emergency situations, such as acute psychosis or agitation. The injectable form can be given intramuscularly (into a muscle) or intravenously (into a vein).
Patient information leaflet
Generic Name: haloperidol
Pronounced: halo-peri-dol
Why do we use haloperidol?
haloperidol is used to treat a variety of psychiatric disorders, including schizophrenia, mania, and Tourette’s syndrome. It is classified as a typical antipsychotic medication and works by blocking dopamine receptors in the brain.
Schizophrenia is a chronic mental disorder characterized by a range of symptoms, including delusions, hallucinations, disorganized thinking, and abnormal motor behavior. haloperidol is effective in treating the positive symptoms of schizophrenia, such as hallucinations and delusions.
Mania is a symptom of bipolar disorder characterized by episodes of elevated, expansive, or irritable mood, along with increased activity and energy levels. Haloperidol is sometimes used in conjunction with other medications to treat mania.
Tourette’s syndrome is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics. haloperidol can be used to help reduce the frequency and severity of tics.
In addition to these specific conditions, haloperidol is sometimes used in emergency settings to control agitation, aggression, and psychosis. It may also be used to manage symptoms associated with dementia in older adults.
ADVERTISEMENT
Brand Name :
Haldol Decanoate, Haldol, Peridol, Haloperidol LA
Synonyms :
haloperidol
Class :
Antipsychotics, 1st generation
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.5 - 5
mg
every 8 hrs
do not exceed the dose of more than 30 mg/day
0.5 - 2
mg
every 8 hrs
moderate: 0.5 to 2 mg orally every 8-12 hours
severe: 3-5 mg orally every 8-12 hours; do not exceed the dose of more than 30 mg/day
2-5 mg intramuscularly (prompt acting) every 4-8 hours as required. In case of acute agitation dose may be required every hour. Do not exceed the dose more than 20 mg/day
(Off-Label)
2-10 mg initially, repeat the bolus dose every 15-30 minutes, sequence wise coupling the initial bolus
After achieving stagnation, administer 25% of last bolus every 6 hours
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.25 - 1
mg
every 12 hrs
5 - 7
days
0.5
mg/day
every 12 hrs
5 - 7
days
Indicated for Psychosis/Sedation, Schizophrenia
For <3 years:
Safety and efficacy are not seen
For 3-12 years (15-40 kg):
0.25-0.5 mg/day orally every 8-12 hours initially; increase by 0.5 mg/day, every 5-7 days as required;
Maintenance dose:
0.05-0.15 mg/kg per day orally every 8-12 hours
For 6-12 years (prompt-acting):
1-3 mg intramuscularly every 4-8 hours as required; do not exceed 0.15 mg/kg per day
For >12 years:
Moderate disease, 0.5-2 mg orally every 8-12 hours initially; in severe disease, 3-5 mg orally every 8-12 hours; do not exceed more than 30 mg/day
Dosage forms & Strengths
Tablet
0.5mg
1mg
2mg
5mg
10mg
20mg
Injectable solution
5 mg/ml
Oral concentrate
2mg/ml
0.25 - 0.5
mg
Orally
every 8 hrs
Tablet
Initially 0.25-0.5 mg orally every 8-12 hours
(Off-Label)
0.25-0.5 mg intravenously every 4 hours